Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of the Poly ADP-ribose polymerase (PARP) inhibitor has expanded swiftly in the last few years. The sector is projected to escalate from a valuation of $8.39 billion in 2024 to about $9.28 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.6%. The expansion during the historic timeframe is due to factors such as clinical studies, regulatory consents, market rivalry, drug mixtures, and patient support initiatives.
In the coming years, the market size of the poly adp-ribose polymerase (parp) inhibitor is projected to expand significantly, reaching a value of$13.81 billion in 2029 with a compound annual growth rate (CAGR) of 10.4%. The potential growth during the forecast period can be associated with factors like extended indications, personalized medical treatments, the evolution of biomarkers, health economics, and burgeoning markets. The forecast period is also expected to witness trending developments in precision medicine, advancements in immunotherapy, targeted treatments, the application of artificial intelligence in the discovery of drugs, and a patient-centered approach in healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
What Are the Core Growth Drivers Propelling the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Forward?
The escalating incidence of ovarian cancer is anticipated to fuel the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer constitutes a malignant tumor that forms in either or both of the female ovaries, the part of the female reproductive system that produces eggs and female hormones. Factors contributing to the growth of ovarian cancer include genetic predisposition, an aging demographic, environmental exposure, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors are implemented in ovarian cancer treatments designed to target DNA repair mechanisms, especially in patients with BRCA mutations. This strategy leads to synthetic lethality and increased tumor cell death. For example, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, projected in February 2024 that the annual number of women succumbing to ovarian cancer will rise to 350,956, marking an increase of nearly 70% from 2022. As a result, the rising incidence of ovarian cancer is promoting the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.
What Segment Types Define the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Structure?
The poly adp-ribose polymerase (parp) inhibitormarket covered in this report is segmented –
1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Ovarian Cancer; Breast Cancer; Other Applications
4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer; Talazoparib For Ovarian Cancer; Talazoparib For Prostate Cancer; Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer; Veliparib For Ovarian Cancer; Veliparib For Non-Small Cell Lung Cancer (Nsclc); Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative); Olaparib For Ovarian Cancer (Brca-mutated); Olaparib For Prostate Cancer (Brca-Mutated); Olaparib For Pancreatic Cancer (Brca-Mutated); Olaparib For Other Cancers
4) By Other Drug Types: Niraparib; Rucaparib; Pembrolizumab (Combination Therapy With Parp Inhibitors); Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing thePoly ADP-Ribose Polymerase (PARP) Inhibitor Industry Evolution?
Prominent businesses in the poly ADP-ribose polymerase (PARP) inhibitor market are working on producing generic PARP inhibitors, which would offer a personalized treatment regimen for cancer patients carrying specific genetic mutations. These inhibitors are drugs that suppress the functionality of the poly ADP-ribose polymerase (PARP) enzyme. For example, in March 2024, Zydus Lifesciences Limited, a pharmaceutical firm based in India, introduced Olaparib, a PARP inhibitor, under the IBYRA brand with the goal of increasing the availability of advanced cancer treatments. IBYRA is capable of acting on specific genetic alterations seen in types of cancer such as breast, ovarian, prostate, and pancreatic, delivering an effective and individualized treatment strategy. This medication is especially advantageous for patients with HRD-positive or BRACA mutations as it helps to stall the advancement of the disease.
View the full report here:
What Is the Definition of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model